Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 7Tumor-Agnostic 3Gastrointestinal 3Other solid neoplasm 2Gynecologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × MK 2206 × Tumor-Agnostic × Clear all
NCT00848718 2019-11-12

MK-2206-003

Merck Sharp & Dohme LLC

Phase 1 Completed
77 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT00670488 2019-04-01

MK-2206-002

Merck Sharp & Dohme LLC

Phase 1 Completed
104 enrolled 28 charts
Tumor-Agnostic

Neoplasms

NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

University of California, San Francisco

Phase 1 Completed
17 enrolled 7 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡